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Abstract
OBJECTIVES: We tested the hypothesis that co-coordinated up-regulation or down-regulation of several ovarian cell
surface kinases may provide clues for better understanding of the disease and help in rational design of therapeutic
targets. STUDY DESIGN:We compared the expression signature of 69 surface kinases in normal ovarian surface epi-
thelial cells (OSE), with OSE from patients at high risk and with ovarian cancer. RESULTS: Seven surface kinases, ALK,
EPHA5, EPHB1, ERBB4, INSRR, PTK, and TGFβR1 displayed a distinctive linear trend in expression from normal, high-
risk, and malignant epithelium. We confirmed these results using semiquantitative reverse transcription–polymerase
chain reaction and tissue array of 202 ovarian cancer samples. A strong correlate was shown between disease-free
survival and the expression ofERBB4. DNAsequencing revealed two novelmutations inERBB4 in two cancer samples.
CONCLUSIONS: A distinct subset of the ovarian surface kinome is altered in the transition from high risk to invasive
cancer and genetic mutation is not a dominant mechanism for these modifications. These results have significant im-
plications for early detection and targeted therapeutic approaches forwomen at high risk of developing ovarian cancer.
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Introduction
Approximately 2% of human genome, corresponding to 433 to 518
genes, code for kinases, which are collectively referred to as the kinome.
The human kinome is involved in multiple functions in the life cycle of
cells, and their differential expression in cancer suggests that protein
kinases play an important role in tumor progression and proliferation.
The pivotal role of individual kinases in the aggressive clinical behavior
of epithelial ovarian cancer (EOC) has been previously demonstrated in
studies of v-erb-b2 erythroblastic leukemia viral oncogene homolog-2
(ERBB-2), vascular endothelial growth factor (VEGF ), and v-erb-b2
erythroblastic leukemia viral oncogene homolog-3 (ERBB-3) [1–3].
Here, we propose that analysis of co-coordinated up-regulation or
down-regulation of several kinases not only will provide more useful un-
derstanding of the disease but also could help in the rational design of
therapeutic targets in EOC.
Differential gene expression profiling with microarray technology
provides a powerful tool to detect and delineate specific signaling path-
ways that may be dysregulated in cancer. In the current study, we eval-
uated the expression pattern of the human kinome in EOC. We
analyzed kinome expression in ovarian surface epithelial cells (OSE)
obtained from patients with normal, high-risk, and cancerous ovaries
using Affymetrix expression array HG-U133 Plus2. We combined
in silico data mining with a detailed literature review to identify a group
of 69 genes encoding for cell surface kinases, which may be targets
for small molecule inhibitors and antibodies. Our analysis led to the
identification of 10 surface kinases differentially expressed in cancer
compared with normal ovarian tissue. Although the kinome profile
of OSE from “high-risk” ovaries did not seem to be different from
normal ovaries, there was a clear linear trend in 7 of the 10 genes with
increased/decreased expression from normal to high risk to cancer
tissues. These were anaplastic lymphoma kinase (ALK ), Eph receptor
A5 (EPHA5), Eph receptor B1 (EPHB1), v-erb-b2 erythroblastic leu-
kemia viral oncogene homolog-4 (ERBB4 ), insulin receptor-related
receptor (INSRR), protein tyrosine kinase 7 (PTK7 ), and transforming
growth factor, β receptor 1 (TGFβR1). Finally, we validated these ob-
servations by tissue microarray (TMA) analysis for four of the seven
genes as well as by reverse transcription–polymerase chain reaction
(RT-PCR). Together, our study demonstrates that differential expres-
sion of kinases could represent early changes in EOC, priming it for
transformation and a multimodal strategy targeting these kinases could
represent a novel therapeutic strategy.
Materials and Methods
Specimen Collection
A total of 18 ovarian samples were collected under an approved
institutional review board protocol (Oregon Health & Science Univer-
sity, IRB #921). The samples were obtained fresh in the operating room
from women undergoing surgery for benign gynecologic disease, from
patients with stage IIIC poorly differentiated ovarian carcinoma at the
time of initial tumor staging/debulking procedure, and from women
undergoing risk-reducing oophorectomy because of significantly ele-
vated risk of developing ovarian cancer. The patients were considered
to be at high risk for ovarian cancer if they had two or more first-degree
relatives with ovarian and/or breast cancer or they had a personal history
of breast cancer and a first-degree relative with breast and/or ovarian
cancer. For this study, we selected high-risk patients that were negative
for BRCA1 and BRCA2 mutations. The numbers of samples and sub-
jects for each group were as follows: five cancer samples (5 subjects), six
normal samples (4 subjects), and seven high-risk samples (5 subjects).
OSE Preparation
Ovarian tissue was mechanically minced in 5 ml of Dulbeccos
phosphate-buffered saline at room temperature and digested with 5 ml
of 0.2% trypsin (Sigma-Aldrich, St Louis, MO) overnight at 4°C. Dis-
sociated epithelial cells were cultured in collagen-coated 35-mm Petri
dish in sterile OSE culture medium (1:1 mixture of RPMI-1640 and
Dulbecco’s modified Eagle’s medium, 20% FBS, 10 μg/ml insulin,
10 ng/ml epidermal growth factor, 1% Pen/Strep, and 0.1% gentamicin)
in a 5% CO2 incubator at 37°C for at least 96 hours. When confluent,
the cells were trypsinized (5 mg/ml Trypsin +7 mM EDTA; Sigma-
Aldrich) and subcultured or harvested for RNA or protein.
Antibodies
Four commercially available primary antibodies were used includ-
ing the polyclonal antibodies to ERBB4, EPHA5, and TGFβR1 (Ab-
gent Envision Proteomics, San Diego, CA) and a monoclonal antibody
to INSRR (R&D Systems, Minneapolis, MN). The control antibodies
to calnexin and α-tubulin were obtained from Sigma-Aldrich. Detec-
tion was performed using the avidin-biotin-peroxidase complex method
(LASB Kit; Dakocytomation, Glostrup, Denmark).
RNA Isolation and Sample Preparation
Approximately 3 × 106 OSE cells were used for the extraction of total
RNA by homogenization in a guanidinium isothiocyanate–based buffer
(RNeasyMicro Kit; Qiagen, Valencia, CA) according to manufacturer’s
instructions. The integrity of the RNA was evaluated by a Bioanalyzer
(Agilent, Palo Alto, CA). The RNA specimens were analyzed using
Affymetrix oligonucleotide array, HG-U133 Plus 2.0 (Affymetrix, Santa
Clara, CA), which contains more than 54,675 probe sets representing
47,000 transcripts and variants as well as 38,500 well-characterized
human genes. Each RNA sample was labeled using a two-step labeling
process. In the first step, messenger RNA (mRNA) was converted to
double-stranded complementaryDNA (cDNA) using Reverse Transcrip-
tase (Invitrogen, Carlsbad, CA) and an oligo-dT primer linked to a T7
RNA polymerase binding site sequence (IDT, Coralville, IA). In vitro
transcription was performed in the second step where the cDNA was
converted to labeled complementary RNA (the target) using T7 RNA
polymerase in the presence of biotinylated UTP and CTP (Enzo Life
Science, Farmingdale, NY). After this linear amplification, the target
was chemically fragmented to produce a uniform distribution of short
complementary RNA (cRNA). Fragmented, biotinylated targets (cRNA
fragments) were combined with hybridization control oligomer (Affy-
metrix) and control cRNA (1.5 pM BioB, 5.0 pM BioC, 25 pM BioD,
and 100 pM Cre-cRNA) in hybridization buffer and applied to the
HG-U133 Plus 2.0 array, which was packaged in a self-contained car-
tridge. The overnight hybridization was followed with staining using
streptavidin-phycoerythrin (SAPE; Molecular Probes, Eugene, OR).
Signal amplification was performed using a biotinylated antistreptavidin
antibody (Vector Labs, Burlingame, CA), followed by a second stain-
ing with SAPE. Scans of the processed chip were performed using the
GeneArray Laser Scanner (Affymetrix).
Gene Expression Analysis
The GeneChip Operating Software (GCOS) was used for image
analysis and signal quantification. The sample performance was eval-
uated using QC/QA parameters including: background, noise (Q),
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average signal intensity, and ratio of signal intensities for probe sets
representing the 5′ and 3′ ends of actin and GAPDH transcripts. Tar-
gets that do not meet predetermined thresholds were remade whenever
possible or discarded from further analysis. In addition, each array was
visually inspected for scratches and nonuniform intensity patterns that
may affect chip performance. After the initial inspection, one cancer
sample was excluded from the statistical analysis owing to poor RNA
quality. Signal data from 17 remaining samples (4 cancers, 6 normal,
and 7 high risks) were normalized using Robust Multiarray Average
using R Bioconductor (http://www.bioconductor.org/). After nor-
malization, the data were examined visually using the box-plot of each
sample, hierarchical clustering of samples, and multidimensional scal-
ing of samples based on all 54,675 probe sets. After verifying the data
quality, we selected 203 probe_sets that represented 69 preselected
kinase genes.
EST and SAGE (Serial Analysis of Gene Expression) data set gen-
erated in our laboratory, combined with all other publicly available
human transcript data, the Oncomine Microarray Database (http://
141.214.6.50/oncomine/main/index.jsp) was used to identify
69 members of the Ovarian Surface Kinome as listed in Table W1.
For each of the selected 203 probe sets for these kinases, we per-
formed analysis of variance to compare the mean expression levels
among cancer, high-risk, and normal groups. In addition, a linear
contrast was generated to determine whether there was a linear trend
between normal, high-risk, and cancer samples. Owing to the small
sample size, we did not adjust for potential within-subject correlation
and treated each sample as an independent observation, although
some patients provided more than one sample. The resulting P values
from F -statistics were adjusted for multiple comparisons using the
false discovery rate (FDR) of Benjamini and Hochberg [4]. The mean
differences between groups were converted to the mean fold change
(FC) by taking anti-log (base 2). Specifically, let Δ = mean difference
(log2 scale). Then FC was defined as: 2
|Δ|, if Δ ≥ 0, and −2|Δ|, if Δ < 0.
Therefore, FC = 2 implies two-fold change in the positive direction
(up-regulation), whereas FC = −2 implies two-fold change in the neg-
ative direction (down-regulation). Genes with FDR less than 15% are
considered differentially expressed and subsequently analyzed by DNA
sequencing and tissue arrays. All statistical analyses were performed us-
ing Statistical Analysis System [5]. Affymetrix NetAffx Center (http://
www.affymetrix.com/analysis/index.affx) was used to obtain additional
biologic information on differentially expressed genes. Annotation in-
formation included the putative gene description, as well as external
identifiers to UniGene and LocusLink, Gene Ontology (GO) func-
tions, and pathway information [6].
Tissue Microarray Preparation
Paraffin-embedded tissues from 202 patients with ovarian cancer
were used to construct the microarrays as described previously by
Kononen et al. [7]. Sections were incubated with ERBB4, EPHA5,
TGFβR1, and INSRR antibodies at room temperature. The biotin-
free HRP enzyme-labeled polymer of the Envision Plus Detection
System (Dakocytomation) was used as a secondary reagent. The diami-
nobenzidine complex was used as a chromogen. In negative controls, a
normal goat serum was used instead of the primary antibody. The
extent of immunochemical reactivity was graded based on intensity
as follows: 0 (negative), 1+ (weak), 2+ (moderate), 3+ (strong). Nega-
tive control slides omitting the primary antibody were included in all
assays. Every attempt was made to evaluate OSE staining only; how-
ever, that was not entirely possible in cancer cases because of the almost
complete change of surface architecture.
Semiquantitative Reverse Transcription
One microgram of RNA from two normal, two high-risk, and two
cancer samples (from the initial cohort of 18 patients) was reverse-
transcribed in the presence of 50-nM random hexamer (NEB, Ipswich,
MA) and AMV Reverse Transcriptase (Promega, Madison, WI) by
incubating at 65°C for 5 minutes followed by cooling on ice for 5 min-
utes and then synthesizing the cDNA at 48°C for 40 minutes. PCR
was subsequently performed to analyze expression of ALK, EPHA5,
EPHB1, ERBB4, INSRR, PTK7, and TGFβR1. The primers are listed
in Table W2.
Amplification for all gene products was for 1 minute at 94°C and
for 30 or 35 cycles at 94°C for 30 seconds, 60°C for 30 seconds, and
72°C for 45 seconds. A final extension cycle at 72°C for 10 minutes
was designed at the end of cycling to ensure complete synthesis. The
PCR products were visualized by separation on a 3% agarose gel after
staining with ethidium bromide. The assessment of FC was made by
scanning the images and subsequent densitometry of the signal using
Quantity One 1-D Analysis Software (Bio-Rad Laboratories, Hercules,
CA). Relative changes were calculated by determining the ratio of ex-
perimental signal intensity to that of the internal control (normalized
GAPDH signal) for each sample for each probe set. The fold increase
is represented as compared with the signals from normal samples for
each normalized gene. The standard deviation representative of variance
between three independent replicates was calculated.
DNA Sequencing
Twenty-nine pairs of primary poorly differentiated serous stage
IIIC ovarian carcinomas samples with matched normal blood DNA
samples were used in mutation screening. Multiple displacement am-
plification (MDA) was performed to provide sufficient quantities of
DNA for mutation screening. One hundred nanograms of genomic
DNA from samples was subjected to MDA. The reaction volume
was 250 μl with an expected yield of 150 to 250 μg of MDA-DNA
as measured by double-stranded DNA quantification (PicoGreen;
Invitrogen). Two diagnostic loci (WIAF-1004 and WIAF-699) in the
MDA-DNA were analyzed by real-time quantitative PCR for ensuring
the integrity of the amplified sample. A locus representation of 100%
indicates nonbiased amplification of the original genomic DNA.
The analysis revealed that all samples correspond to the “highly usable”
category defined by greater than 3% of locus representation with a ratio
of less than 20-fold between the two loci. The genetic identities of
29 matching normal and ovarian cancer DNA (GBM19) were con-
firmed by 16 highly polymorphic markers. Seven receptor kinase genes
showing linear trend in expression from normal to high risk to cancer
(ALK, EPHB1, EPHA5, ERBB4, TGFβR1, INSRR, and PTK7 ) were
selected for mutation screening. Coding exons and intron-exon splicing
junctions of selected genes were sequenced.Detailedmethods for primer
design, PCR sequencing, and data analysis are described elsewhere [8].
All primer sequences are available on request.
TMA Statistical Analysis
An independent set of 202 ovarian cancer samples arranged as TMA
was analyzed for statistical correlates, as described in the section for gene
expression. Clinical variables were available for all 202 cases and are
summarized with proportions, means, or quartiles as described in the
Results section. Kendall τ was used to measure the association between
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ordered variables such as the staining intensities of EPHA5, ERBB4,
INSRR, and TGFβR1. Kaplan-Meier method was used to estimate
disease-free survival (DFS) as well as overall survival (OS), and log-rank
tests were used to compare survival curves between groups defined by
the staining intensity for each gene. Confidence intervals for survival
curves were based on asymptotic Wald statistics on log scale.
Results
The Expression Profile of Ovarian Surface Kinome
The examination of selected 69 cell surface kinase expression re-
presented by a total of 203 probe_set IDs in OSEs revealed a total of
10 genes (16 probe_sets) that were differentially expressed in at least
one of the three paired comparisons between normal, high-risk, and
cancer groups. Of these, 7 genes (12 probe_sets) were differentially ex-
pressed (i.e., FDR adjusted, P < .15) between cancer and normal groups
(Table 1). Six genes (10 probe_sets) were differentially expressed be-
tween cancer and high-risk OSEs. The overlap between these two sub-
sets involved three genes: EPHA5, EPHB1, and TGFβR1. None of the
total 203 probe sets were differentially expressed between normal versus
high-risk OSEs.
We performed a linear trend analysis for all 10 genes. Seven genes,
ALK, EPHA5, EPHB1, ERBB4, INSRR, PTK7, andTGFβR1, displayed
a distinctive linear trend of expression from normal to high risk to cancer
(Figure 1). The seven genes showing a linear trend of expression are the
same seven genes found to be differentially expressed in comparison be-
tween cancer and normal groups.
DNA Sequencing Revealed Two Independent Intronic
Mutations in ERBB4
To test whether observed alterations in gene expression are a conse-
quence of genetic mutations, bidirectional dideoxy sequencing using
the high-throughput sequencing pipeline at the Venter Institute’s Joint
Table 1. Human Kinome Genes Upregulated or Downregulated among Normal (N), High-Risk (HR), and Cancer (C) Samples (P < .15).
Probe Set ID Gene*
Symbol
HR vs N,
Adjusted P
HR vs N,
FC
HR vs N,
Change
C vs HR,
Adjusted P
C vs HR,
FC
C vs HR,
Change
C vs N,
Adjusted P
C vs N,
FC
C vs N,
Change
208212_s_at ALK 0.214 1.2141 No Change 0.7029 1.07 No Change 0.0572 1.2991 Up
202686_s_at AXL 0.5475 −1.1746 No Change 0.0864 1.5104 Up 0.4068 1.2859 No Change
203499_at EPHA2 0.2737 −1.5464 No Change 0.052 1.8854 Up 0.5547 1.2192 No Change
215664_s_at EPHA5 0.8856 1.0971 No Change 0.052 2.6911 Up 0.0561 2.9525 Up
237939_at EPHA5 0.9119 1.0421 No Change 0.037 2.6485 Up 0.0331 2.7601 Up
241404_at EPHA5(1) 0.8932 1.0617 No Change 0.052 2.3999 Up 0.0561 2.5479 Up
210753_s_at EPHB1 0.9119 1.0265 No Change 0.052 1.6876 Up 0.0561 1.7324 Up
211898_s_at EPHB1 0.9119 −1.0179 No Change 0.052 1.3723 Up 0.0776 1.3482 Up
217324_at EPHB1(2) 0.2737 1.167 No Change 0.8363 1.0405 No Change 0.0776 1.2143 Up
230425_at EPHB1 0.7541 −1.3002 No Change 0.068 4.7333 Up 0.1857 3.6403 No Change
241581_at ERBB4(3) 0.4725 1.102 No Change 0.3951 1.1199 No Change 0.0776 1.2341 Up
215776_at INSRR 0.2737 1.1672 No Change 0.8969 1.0236 No Change 0.1462 1.1948 Up
203131_at PDGFRA 0.5261 1.4736 No Change 0.052 −3.084 Down 0.2339 −2.0928 No Change
1555324_at PTK7 0.3554 −1.3193 No Change 0.6761 −1.1565 No Change 0.0776 −1.5257 Down
224793_s_at TGFBR1 0.7272 1.132 No Change 0.1564 1.6893 No Change 0.0776 1.9122 Up
236561_at TGFBR1 0.9442 1.0141 No Change 0.052 1.6841 Up 0.0671 1.7078 Up
(1), (2), and (3) indicates that the gene symbol was unavailable in March 2008 annotation. The other 13 annotations are unchanged.
*Gene symbols are based on June 2005 Annotations from the Netaffx Analysis Center (http://www.affymetrix.com/analysis/index.affx).
Figure 1. Linear trend of expression for the seven differentially expressed genes. The normalized mean Log2 intensities with 95% confi-
dence interval were plotted on the y-axis and the probeset_ids for each ordinal group on the x-axis. Different color lines denote each
probe_set across the three experimental groups. ALK, EPHA5, EPHB1, ERBB4, and INSRR show an increasing trend, whereas PTK7 seems
to be negatively modulated.
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Technology Center was performed. Two novel mutations were detected
in ERBB4 in two different cancer samples. A somatic mutation C/C
to C/Twas identified in intron 5 in the cancer sample TU14085 (Fig-
ure 2A). The mutation was located at 25,210-bp 3′ of exon 5 (ENSE-
00001309248) and 233-bp 5′ of exon 6 (ENSE00001231844). A
somatic mutation T/T to T/C was identified in intron 27 in tumor
TU0412302 (Figure 2B). The mutation was located at 2476-bp 3′ of
exon 27 (ENSE00001302849) and 315-bp 5′ of exon 28 (ENSE-
00001330493). Representative sequence traces are shown in Figure 2
(A and B). The functional consequences of the two mutations are
uncharacterized; however, the association of intron 5 mutation with
ErbB4 protein overexpression in TU14085 (data not shown) may sug-
gest a functional significance of the mutation. We found no mutations
in ALK, EPHA5, EPHB1, INSRR, TGFβR1, and PTK7.
Select Kinases Are Overexpressed in Most Human
Ovarian Cancers
On the basis of the results of our gene expression studies, DNA se-
quencing studies, and availability of antibodies, we selected a subset of
genes (EPHA5, ERBB4, INSRR, and TGFβR1) for further validation
at the protein level. Immunohistochemistry was used to test an inde-
pendent set of 202 ovarian cancer samples of all stages in TMA. Scored
staining profile is shown in Table 2A. The ERBB4 staining was positive
in 195, EPHA5 in 177, TGFβR1 in 105, and INSRR in 97 of the 202.
Figure 2. Somatic point mutations in ERBB4 gene in two ovarian carcinomas by resequencing. The panels on the left show forward and
reverse sequence trace file from tumor and the right panel shows matched blood sample. (A) Intron 5 displayed a mutation in matched
samples from tissue and blood. An acquired T/T to T/C mutation is identified in intron 5 as highlighted base in the trace. (B) Intron 27 C/C
to C/T acquired mutation is identified in the sequence panel as a highlighted base. For full description, see Results section.
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The pattern of staining differed among the markers: ERBB4 demon-
strated intense cytoplasmic, nuclear, and membranous staining. In
contrast, EPHA5 reactivity was predominantly cytoplasmic and, to
a lesser degree, nuclear (Table 2A), and INSRR resulted in exclusively
cytoplasmic staining. The TGFβR1 staining pattern appeared to be dif-
fuse cytoplasmic, whereas INSRR staining appeared to be in punctate
bodies around the nucleus or cell junctions (Table 2A).
Several associations were observed. The intensity of staining for
ERBB4 and EPHA5 was positively correlated (τ = 0.38, P < .0001)
as well as that for ERBB4 and TGFβR1 (τ = 0.13, P < .049) and for
EPHA5 and TGFβR1 (τ = 0.12, P < .048). The nuclear staining
pattern was associated with a higher staining intensity for both ERBB4
and EPHA5 (P < .0001 each).
Several disease associations were observed. The intensity of staining
for ERBB4 and EPHA5 was positively correlated (τ = 0.38, P < .0001)
as well as that for ERBB4 and TGFβR1 (τ = 0.13, P < .049) and for
EPHA5 and TGFβR1 (τ = 0.12, P < .048). The nuclear staining
pattern was associated with higher staining intensity for both ERBB4
and EPHA5 (P < .0001 each).
TMA and Clinical Correlation
The characteristics of study population are presented in Table 3. The
median age was 61 years (range, 33-89 years). Most patients presented
with grade 3 tumors (84%), stage IIIC (77%), and with serous histo-
logic diagnosis (77%). A complete response to therapy was achieved
in 98 (49%) of the 202, a partial response was achieved in 97 (48%)
of the 202, whereas the remaining 7 patients showed no response. The
median estimated OS for all patients was 40.8 months (confidence
interval [CI], 30.1-48.0 months), whereas the median DFS was 20.6
months (CI, 17.4-35.9 months). The 5-year DFS and OS for all
Table 2. TMA Profile of Ovarian Carcinoma.
(A) Immunocytochemistry: Intensity and Pattern of Staining for the Four Chosen Antibodies
Intensity TGFβR1 ErbB-4 EphA5 INSRR
No. Cases/Total Percentage, % No. Cases/Total Percentage, % No. Cases/Total Percentage, % No. Cases/Total Percentage, %
0 94 46.5 2 1.0 16 7.9 2 1.0
1 58 28.7 39 19.3 66 32.7 11 5.4
2 24 11.9 44 21.8 60 29.7 43 21.3
3 23 11.4 112 55.4 51 25.2 43 21.3
3 N/A 0 0.0 5 2.5 9 4.5 0 0.0
Pattern of staining in the TMA being studied
Nuclear 77 38.1 75 37.1 2 1.0 0 0.0
Nonnuclear 118 58.4 120 59.4 118 58.4 99 49.0
Table 3. TMA: Cases Characteristics (N = 202).
Age, median (range), years 61 (33-89)
Follow-up (median), months
FIGO stage, n (%)*
I 8 (4%)
II 10 (5%)
III 155 (77%)
IV 23 (11%)
Histology, n (%)*
Serous 156 (77%)
Clear cell 10 (5%)
Endometrioid 8 (4%)
Mucinous 5 (2%)
Undifferentiated 3 (1%)
Mixed 12 (6%)
Grade, n (%)*
1 9 (4%)
2 16 (8%)
3 169 (84%)
Residual tumor*
None 64 (32%)
Present 131 (65%)
Clinical response*
Complete response 98 (49%)
Partial response 97 (48%)
Current status, n (%)
Alive, NED 35 (17%)
Alive with disease 27 (13%)
Dead of disease 134 (66%)
Dead from other causes 6 (3%)
FIGO indicates the International Federation of Gynecology and Obstetrics; NED, no evidence
of disease.
*Six patients were unstaged (3%), the grade was not determined in 8 (4%), 4 (2%) had carcino-
sarcoma histologic type, residual tumor and clinical response were not assessed in 7 (3%).
(B) Semiquantitative RT-PCR: Relative Intensity of Select Kinases in Normal, High-Risk, and Cancer Cells
Gene Sample Type Normalized Mean FC with Respect to Normal*,† SD
ERBB4 Normal 1.00 0.089
High risk 2.64 0.023
Cancer 5.24 0.115
EPHB1 Normal 1.00 0.193
High risk 1.99 0.038
Cancer 10.69 0.441
PTK7 Normal 1.00 0.170
High risk 0.45 0.152
Cancer 0.19 0.070
TGFβR1 Normal 1.00 0.243
High risk 1.85 0.109
Cancer 2.92 0.102
*The signal intensities expressed in arbitrary units were adjusted for the background intensities for that lane and then the resulting intensities from three experiments were averaged.
†Normalized ratios were calculated by dividing the normalized intensities by the values obtained for normal tissue for that gene.
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patients in this group were 30.4% (CI, 23.9%-38.6%) and 22.5% (CI,
14.8%-34.3%), respectively. Kaplan-Meier statistics revealed a trend
for patients with ERBB4-positive tumors to have a longer DFS and
OS, although the association did not reach statistical significance.
Log-rank test comparison identified that the gradual increase in both
DFS and OS positively correlated with the intensity of ERBB4 staining:
patients whose tumors expressed higher ERBB4 staining had a longer
DFS (χ 2 = 5.0, P = .08; Figure 3, A and B). Similarly, there was weak
evidence that the OS probability is different for different levels of
ERBB4 intensity (χ 2 = 3.2, P = .20) where higher levels were associated
with longer survival (Figure 3B). There was no correlation between the
pattern of ERBB4 staining (nuclear vs membranous) and survival.
Semiquantitative RT-PCR Confirms That a Linear Trend
Exists in the Select Group of Surface Kinases between Normal,
High-Risk, and Cancer OSE
Semiquantitative PCR was used in an independent set of normal,
high-risk, and cancerous primary OSE that were of low passage as a
confirmatory assay for changes in ALK, EPHA2, EPHA5, EPHB1,
ERBB4, INSRR, TGFβR1, and PTK7. We found that both methods
(microarray analysis and semiquantitative RT-PCR) detected similar
patterns for the overexpressed and underexpressed genes selected for
validation. The data revealed that in comparison to normal ovarian sur-
face epithelial cells, high-risk OSE demonstrated 2-fold up-regulation
of EPHB1, 2.6-fold up-regulation of ERBB4, 1.8-fold up-regulation of
TGFβR1, and 0.45-fold down-regulation of PTK7. Similar analysis
with cancer EOC showed 10.69-fold up-regulation of EPHB1, 5.2-fold
up-regulation of ERBB4, 2.9-fold up-regulation of TGFβR1, and
approximately 0.2-fold down-regulation of PTK7. The quantitative
data are shown in Table 2B.
Discussion
Protein kinases play a prominent role in many developmental and cel-
lular processes. To identify new oncogenic activation mechanism in
ovarian cancer, we studied the surface kinome of OSE derived from
individuals who are known to be at significant risk of ovarian cancer
based on family history and compared with OSE derived from indi-
viduals at low risk and with OSE derived from invasive ovarian cancer.
Because BRCA1/2 mutations account for only a fraction of inher-
ited predisposition to ovarian cancer, mutation carriers were excluded
from this analysis in an effort to identify novel oncogenic processes.
This study represents the first systematic analysis of the ovarian sur-
face kinome spanning the spectrum of normal, high-risk, and malig-
nant epithelium.
Complementary techniques that included gene expression analysis,
semiquantitative RT-PCR, DNA sequence analysis of selected kinases,
and independent TMA of ovarian cancer specimens were used as vali-
dation in our study. Several novel observations resulted from these
sets of experiments. It was anticipated that the magnitude of changes
in gene expression between the high-risk and the normal tissue would
be subtle at best because the ovaries removed prophylactically from
high-risk women are often morphologically and histologically similar
to normal ovarian tissues. Indeed, we found no distinction in the expres-
sion of the 69 surface receptor kinases between high-risk and normal
samples and identified a distinct difference in the expression of a subset
of kinases between cancer and high risk on one hand, and cancer and
normal ovaries on the other. Significant differences in expression of
EPHA5, EPHB1, and TGFRβR1 were observed when cancer samples
were compared to both normal OSE and high-risk OSE, whereas
AXL, EPHA2, and PDGFRA demonstrated a differential expression
pattern unique to high-risk OSE. In addition, ALK, INSRR, PTK7,
Figure 3. Kaplan-Meier plots showing estimated survival for patients with low, medium or high ERBB4 expression levels. (A) A trend toward
longer DFS is associated with a higher ERBB4 expression in ovarian TMA (P = .08). The red line represents patients with low ERBB4 ex-
pression, green line represents the projected survival for medium levels of ERBB4 protein in the tumors, and the blue line represents highest
level of ERBB4 expression. Details of how the levels were assigned are described in the Materials and Methods section. (B) The ERBB4:
protein expression and OS. Higher levels of ERBB4 protein expression are associated with longer OS (P= .2). 1. Red line = low expression;
2. green line = medium; 3. blue line = high ERBB4 expression level.
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and ERBB4 differential expression was detected between cancer and
normal subsets alone. The distinct subset of surface kinases over-
expressed when high-risk OSEs are compared with cancer (EPHA2,
AXL, and PDGFRA) could be considered critical in the transition from
high-risk to frank invasive carcinoma. AXL expression has been reported
in a wide variety of human cancers including ovarian and shown to be
involved in cancer progression [9]. In addition, EPHA2 was recently
shown to promote ovarian tumor growth by enhancing cell–extracellular
cell matrix adhesion, increasing anchorage-independent growth, and
promoting angiogenesis [10]. Whereas the successive linear transfor-
mation of the OSE from normal to high-risk to malignant epithelium
seems to be supported by our data from this small cohort of samples,
alternative pathway may exist in which accumulation of the genetic
changes directly transform a normal cell to the malignant one (Table 1,
comparison: Cancer vs Normal).
An extended analysis rendered 7 genes within the identified 10 kinase
gene set with a significant linear trend of overexpression (ALK, EPHA5,
EPHB1, ERBB4, INSRR, and TGFβR1) and underexpression (PTK7).
To assess the apparent clinicopathologic relevance of the seven kinases
identified, a comprehensive expression analysis in a large panel of
ovarian carcinoma was performed. Our results indicate that ERBB4
and EPHA5 had the highest frequency of expression in 96% and
87% of the cases, respectively. Increased expression of Eph receptor
tyrosine kinases and their respective ephrin ligands has been implicated
in tumor progression in a number of malignancies including melanoma,
cancer of the breast, prostate, stomach, colon, and small cell lung cancer
[11]. Herath et al. [12] reported a striking correlation of EPHA5mRNA
overexpression with poor survival in ovarian cancer. Because this class of
genes is involved in cell-cell communication, it is not surprising that the
altered expression inmalignancies correlates with increased invasiveness,
increased metastatic potential, and poor outcome.
Consistent with previous reports [13], both ERBB4 mRNA and
protein were overexpressed in most samples in our study [13], and
the staining was mostly membranous and, to a lesser extent, nuclear
[14]. Interestingly, ERBB4 expression in the tumors correlated with
both DFS and OS of ovarian cancer patients. The intensity of ERBB4
staining was also positively correlated with survival. The overexpression
of ERBB4 has been associated with improved survival in breast cancer
patients as well [15]. Although this association has not been functionally
explained in either breast or ovarian cancer, it has been shown that
ERBB4 modulates cell death pathway [16,17]. Its intracellular domain
contains a BH3 subdomain that interacts with BAK, crucial for the
death induction and dimerization of BAK, resulting in cytochrome c
release, heralding apoptosis [16]. It is therefore possible that ERBB4
overexpression predisposes cancer cells toward more efficient apoptosis,
which may reflect in longer DFS and OS.
Because distinct isoforms of ERBB4 and other surface kinases iden-
tified in our study could be generated at the transcriptional levels, we
also tested whether somatic mutations or polymorphisms may underlie
the observed differential expression patterns in the seven genes that
demonstrated a linear trend. We sequenced these genes in an indepen-
dent set of 29 stage III serous ovarian carcinomas. Two independent
mutations were identified in the noncoding region of ERBB4 of two
samples. ERBB4 intron 5 mutation was associated with overexpression
of the ERBB4 mRNA and protein, insinuating that abnormal ERBB4
mRNA splicing resulted in overexpression of the ERBB4 in tissue.
Alternatively, a transcriptional enhancing function of this intronic mu-
tation might exist, influencing transcription elongation. In a previous
study, Soung et al. [18] detected a total of 12 mutations in the ERBB4
gene. These were somatic mutations in 3 (1.7%) of 180 gastric carci-
nomas, 3 (2.9%) of 104 colorectal carcinomas, 5 (2.3%) of 217 non–
small cell lung cancers, and 1 (1.1%) of 94 breast carcinomas. Of the
12 ERBB4 mutations detected in this study, 3 were found in the in-
trons. The mutations that we report in this study have not been previ-
ously defined. Although the functional consequences of the mutation
are not known, the intron 27 mutation is located in a conserved base of
a FOX03/04 binding site, and the intron 5 mutations is in a conserved
base of a CREB transcription factor binding site. This might have an
implication in transcriptional regulation of this gene. We are currently
exploring this possibility.
We queried the Oncomine database (http://www.oncomine.org)
[19] for the expression of the seven kinases in thirteen ovarian cancer
studies deposited as of February 2008 (Table W3) [2,18–23]. Each
study measured a variety of clinical and pathologic aspects of patients
with disease (stage, grade, histologic type, DFS), and they represent 687
independent cases of ovarian cancer. Oncomine expression correlations
were searched for each gene, and the results were filtered by selecting
ovarian tumors. Statistical analysis of differences was performed using
ONCOMINE algorithms to account for the multiple comparisons
among different studies, similar to a meta-analysis, as previously de-
scribed [17]. Interestingly, the Oncomine data largely support some
of our results. Notably, ALK, TGFβR1, EPHA5, INSRR, and ERBB4
were dysregulated in more advanced disease stages and associated with
more aggressive tumors [2,20,21,23–25]. Similar to our results, Lu et al.
[2,20,21,23–25] reported that overexpression of ERBB4 was associated
with more favorable 5-year survival.
The results of this study have several implications. First, the critical
role for a subset of surface kinases in the progression from “high-risk”
OSE to cancer is apparent. Second, a subset of differentially over-
expressed surface kinases is shared when normal or high-risk OSE is
compared with cancer. Third, the overexpression of one of the surface
receptor kinases (ERBB4) conferred a higher DFS of the cancer pa-
tients. These data suggest that surface receptor kinases (ALK, EPHA5,
EPHB1, ERBB4, INSRR, PTK, and TGFβR1) could play a role in the
early stages of ovarian cancer development, and the lack of somatic
mutations in most of these kinases suggest the possibility that post-
transcriptional modifications or epigenetic regulation are the dominant
mechanisms by which these kinases contribute to OSE cancer develop-
ment. Even in high-risk individuals with known BRCA1/2 mutations,
these kinases may act as “modifiers” of risk and penetrance. Although
the ability to determine the appropriate context to functionally assess
the coordinate regulation of the identified surface kinases in this study
may be tedious and time consuming, our data indicate that these efforts
will be worthwhile to determine whether these kinases should be se-
lected with high priority for molecularly targeted prevention and thera-
peutic studies.
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Table W1. List of 69 Ovarian Cell Surface Kinase Genes (203 Probes).
ProbeSet_id Gene Name Gene Symbol Ref Seq Kinase Normal Ovary*
ESTS SAGE
1 203935_at Activin A receptor, type I ACVR1 NM_001105 STE 21.7 0
2 205209_at, 205209_at, 208218_s_at,
208219_at, 208222_at, 208223_s_at,
213198_at
Activin A receptor, type IB ACVR1B NM_004302 STE 21.7 2.1
3 205327_s_at, 228416_at Activin A receptor, type IIA ACVR2 NM_001616 STE 0 0
4 220028_at, 236126_at, 1559548_at Activin A receptor, type IIB ACVR2B NM_001106 STE 0 0
5 1552519_at Activin A receptor, type IC ACVR1C NM_145259 STE 0 0
6 236126_at Activin A receptor type II-like 1 ACVRL1 NM_000020 STE 0 0
7 208211_s_at, 208212_s_at Anaplastic lymphoma kinase (Ki-1) ALK NM_004304 TK 0 0
8 206892_at Anti-Mullerian hormone receptor, type II AMHR2 NM_020547 STE 0 0
9 202686_s_at AXL receptor tyrosine kinase AXL NM_001699 TK 21.7 8.4
10 204832_s_at, 213578_at Bone morphogenetic protein receptor, type IA BMPR1A NM_004329 STE 0 2.1
11 210523_at Bone morphogenetic protein receptor, type IB BMPR1B NM_001203 STE 0 0
12 209920_at,210214_s_at, 225144_at,
231873_at, 238516_at
Bone morphogenetic protein receptor, type II (serine/threonine kinase) BMPR2 NM_001204 TKL 21.7 10.5
13 203104_at Colony stimulating factor 1 receptor, formerly McDonough feline
sarcoma viral (v-fms) oncogene homolog
CSF1R NM_005211 TK 21.7 0
14 207169_x_at, 208779_x_at, 210749_x_at Discoidin domain receptor family, member 1 DDR1 NM_001954 TK 21.7 10.5
15 205168_at, 225442_at, 227561_at,
235631_at
Discoidin domain receptor family, member 2 DDR2 NM_006182 TK 0 10.5
16 1565483_at, 1565484_x_at Epidermal growth factor receptor (erythroblastic leukemia viral
(v-erb-b) oncogene homolog, avian)
EGFR NM_005228 TK 21.7 0
201983_s_at, 201984_s_at
210984_x_at, 211550_at
211551_at, 211607_x_at
17 205977_s_at, 215804_at EPH receptor A1 EPHA1 NM_005232 TK 0 0
18 203499_at EPH receptor A2 EPHA2 NM_004431 TK 0 16.8
19 206070_s_at, 206071_s_at, 211164_at EPH receptor A3 EPHA3 NM_182644 TK 0 0
20 206114_at, 227449_at, 228948_at,
229374_at
EPH receptor A4 EPHA4 NM_004438 TK 0 0
21 215664_s_at, 216837_at, 237939_at EPH receptor A5 EPHA5 NM_004439 TK 0 0
22 1561396_at, 233184_at EPH receptor A6 EPHA6 NM_173655 TK 0 0
23 1554629_at, 206852_at, 238533_at EPH receptor A7 EPHA7 NM_004440 TK 0 0
24 1554069_at, 231796_at EPH receptor A8 EPHA8 NM_020526 TK 0 0
25 1553371_at, 236073_at, 243717_at EPH receptor A10 EPHA10 NM_173641 TK 0 0
26 210753_s_at, 211898_s_at, 230425_at EPH receptor B1 EPHB1 NM_004441 TK 0 0
27 209588_at, 209589_s_at, 210651_s_at,
211165_x_at
EPH receptor B2 EPHB2 NM_004442 TK 0 4.2
28 1438_at, 204600_at EPH receptor B3 EPHB3 NM_004443 TK 0 0
29 202894_at, 216680_s_at EPH receptor B4 EPHB4 NM_004444 TK 43 2.1
30 204718_at EPH receptor B6 EPHB6 NM_004445 TK 0 0
31 210930_s_at, 216836_s_at, 234354_x_at V-erb-b2 erythroblastic leukemia viral oncogene homolog 2,
neuro/glioblastoma derived oncogene homolog (avian)
ERBB2 NM_004448 TK 0 2.1
32 1563252_at, 1563253_s_at, 202454_s_at,
215638_at, 226213_at
V-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) ERBB3 NM_001982 TK 0 27
33 206794_at, 214053_at, 233494_at,
233498_at
V-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) ERBB4 NM_005235 TK 0 0
34 207822_at, 207937_x_at, 210973_s_at,
211535_s_at, 215404_x_at, 222164_at,
226705_at
Fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2,
Pfeiffer syndrome)
FGFR1 NM_015850 TK 43 4.2
35 1560859_at, 203638_s_at, 203639_s_at,
208225_at, 208228_s_at, 208229_at,
208234_x_at, 211398_at, 211399_at,
211400_at, 211401_s_at, 240913_at
Fibroblast growth factor receptor 2 (bacteria-expressed kinase,
keratinocyte growth factor receptor, craniofacial dysostosis 1,
Crouzon syndrome, Pfeiffer syndrome, Jackson-Weiss syndrome)
FGFR2 NM_000141 TK 0 10.5
36 204379_s_at, 204380_s_at Fibroblast growth factor receptor 3 (achondroplasia, thanatophoric
dwarfism)
FGFR3 NM_000142 TK 0 6.3
37 1554961_at, 1554962_a_at, 204579_at,
211237_s_at
Fibroblast growth factor receptor 4 FGFR4 NM_002011 TK 0 0
38 204406_at, 210287_s_at, 222033_s_at,
232809_s_at
Fms-related tyrosine kinase 1 (vascular endothelial growth factor/
vascular permeability factor receptor)
FLT1 NM_002019 TK 21.7 0
39 206674_at Fms-related tyrosine kinase 3 FLT3 NM_004119 TK 0 0
40 210316_at, 229902_at, 234379_at Fms-related tyrosine kinase 4 FLT4 NM_182925 TK 21.7 0
41 207851_s_at, 213792_s_at, 226212_s_at,
226216_at, 226450_at
Insulin receptor INSR NM_000208 TK 65 0
42 203627_at, 203628_at, 208441_at, 225330_at,
243358_at
Insulin-like growth factor 1 receptor IGF1R NM_000875 TK 65 0
43 215776_at Insulin receptor-related receptor INSRR NM_014215 TK 0 0
44 203934_at Kinase insert domain receptor (a type III receptor tyrosine kinase) KDR NM_002253 TK 0 2.1
45 205051_s_at KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral KIT NM_000222 TK 0 0
46 206223_at, 235307_at Lemur tyrosine kinase 2 LMTK2 NM_014916 TK 0 0
47 1557103_a_at Lemur tyrosine kinase 3 LMTK3 XM_055866 TK 0 0
48 207106_s_at, 217184_s_at Leukocyte tyrosine kinase LTK NM_002344 TK 0 0
Table W2. Oligonucleotide Primers Used in the Semiquantitative RT-PCR Analysis.
Oligonucleotide Sequence Orientation with Respect to the Transcript Base Alignment in the Gene Gene Exon/Intron Boundary
CAGTGTGACAGTGAGCGACC S 1343 EphA2 Exon 5
cgcaTTGGAGTCTCCCTTCTTGc AS 1557 EphA2 Exon 6, 7
CAGTGGAAGTTGCTGCGAATG S 2812 EphA5 Exon 16
ggcccatcttgattgcctctagcca AS 2990 EphA5 Exon 17
TGCGCTTCACTGTGAGAGAC S 266 EphB1 Exon 10
GAAAGAAGAGACATACAGGCTCC AS 563 EphB1 Exon 11, 12
GACCCTGGTACTTGTGAAGAGCC S 266 PTK7 N/A
CATAGGGCCACCTTCTGCTTGGT AS 563 PTK7 N/A
AATCAAGTACCGCCGCTTG S 2823 INSRR Exon 13
gcGGTTCTGTTTCTCTTCTTGCcG AS 3083 INSRR Exon 15, 16
cggaaAGGGCTAAACGGCAATTCcG S 3530 ALK Exon 15
GATGCCCAGTGGACTGATGAAG AS 3778 ALK Exon 17
cagctaggcttacagcattgcgga S 1515 TGFBR1 Exon 9
atgatctccagcacagcagag AS 1912 TGFBR1 Exon 11, 12
Table W1. (continued )
ProbeSet_id Gene Name Gene Symbol Ref Seq Kinase Normal Ovary*
ESTS SAGE
49 N/A Similar to bone morphogenetic protein receptor, type IA precursor;
activin A receptor, type II-like kinase 3
LOC283155 XM_208545 STE 0 0
50 206028_s_at, 211912_at, 211913_s_at, 233079_at C-mer proto-oncogene tyrosine kinase MERTK NM_006343 TK 0 0
51 205455_at Macrophage stimulating 1 receptor (c-met-related tyrosine kinase) MST1R NM_002447 TK 0 0
52 203510_at, 211599_x_at, 213807_x_at, 213816_s_at Met proto-oncogene (hepatocyte growth factor receptor) MET NM_000245 TK 0 0
53 207632_at, 207633_s_at, 241122_s_at, Muscle, skeletal, receptor tyrosine kinase MUSK NM_005592 TK 21.7 0
54 208605_s_at Neurotrophic tyrosine kinase, receptor, type 1 NTRK1 NM_002529 TK 0 2.1
55 207152_at, 214680_at, 221795_at, 221796_at,
229463_at, 236095_at
Neurotrophic tyrosine kinase, receptor, type 2 NTRK2 NM_006180 TK 0 2.1
56 1557795_s_at, 206462_s_at, 215025_at, 215115_x_at,
217033_x_at, 217377_x_at, 228849_at
Neurotrophic tyrosine kinase, receptor, type 3 NTRK3 NM_002530 TK 21.7 0
57 1554828_at, 203131_at, 211533_at, 215305_at Platelet-derived growth factor receptor, alpha polypeptide PDGFRA NM_006206 TK 0 16.8
58 202273_at Platelet-derived growth factor receptor, beta polypeptide PDGFRB NM_002609 TK 108.5 2.1
59 207011_s_at, 1555324_at PTK7 protein tyrosine kinase 7 PTK7 NM_152883 TK 43 40
60 205879_x_at, 211421_s_at, 215771_x_at Ret proto-oncogene (multiple endocrine neoplasia and medullary
thyroid carcinoma 1, Hirschsprung disease)
RET NM_020630 TK 0 0
61 205805_s_at, 211057_at Receptor tyrosine kinase-like orphan receptor 1 ROR1 NM_005012 TK 0 0
62 205578_at Receptor tyrosine kinase-like orphan receptor 2 ROR2 NM_004560 TK 0 0
63 207569_at v-ros UR2 sarcoma virus oncogene homolog 1 (avian) ROS1 NM_002944 TK 0 0
64 202853_s_at, 214172_x_at, 216976_s_at RYK receptor-like tyrosine kinase RYK NM_002958 TK 65 2.1
65 206702_at, 217711_at TEK tyrosine kinase, endothelial (venous malformations, multiple
cutaneous and mucosal)
TEK NM_000459 TK 0 0
66 206943_at, 224793_s_at, 236561_at Transforming growth factor, beta receptor I (activin A receptor
type II-like kinase, 53kDa)
TGFBR1 NM_004612 TKL 0 2.1
67 207334_s_at, 208944_at Transforming growth factor, beta receptor II (70/80kDa) TGFBR2 NM_003242 TKL 0 6.3
68 1560657_at, 204468_s_a Tyrosine kinase with immunoglobulin and epidermal growth factor
homology domains
TIE1 NM_005424 TK 0 18.9
69 211431_s_at, 211432_s_at TYRO3 protein tyrosine kinase TYRO3 NM_006293 TK 21.7 0
*EST and SAGE counts expressed as normalized values per 200,000 sequences.
Table W3. Oncomine Database Analysis of the Expression of Cell Surface Kinases in Ovarian Cancer in 13 Ovarian Cancer Studies.
Gene Study Analysis Observation (No. Patients) P
ALK Hendrix_ Stage Upregulated in stage I (35) vs IV (9) 2.1E-5
Lu Histology Upregulated in clear cell (7), Endometrioid (9), serous (20) vs mucinous (9) 1.2E-4
Hendrix Grade Downregulated in grade 1 (19) vs grade 3 (33) .005
Lu Survival Upregulated in alive (7) vs dead (10) .014
EPHA5 Lu Histology Upregulated in clear cell (7), Endometrioid (9), serous (20) vs mucinous (9) 8.3E-5
Gilks_ Grade Upregulated in low malignant potential (10) vs grade 3 .003
Bild Stage Upregulated in IV (21) vs III (111) .04
EPHB1 Gilks_ Grade Upregulated in low malignant potential (10) vs grade 3 .009
Hendrix Stage Upregulated in stage I (35) vs IV (9) .018
Hendrix Grade Downregulated in grade 1 (19) vs 3 (33) .037
ERBB4 Lu Histology Upregulated in Clear Cell (7), Endometrioid (9), Serous (20) vs Mucinous (9) 5.4E-7
Hendrix Tumor type Upregulated in serous (41) vs normal ovary 3.4E-17
Hendrix Tumor type Upregulated in endometrioid (37) vs normal ovary 1.2E-11
Lu 5 years survival Upregulated in alive (7) vs dead (10) .023
INSRR Hendrix Histology Upregulated in clear cell (8) vs normal ovary (4) .003
PTK7 Lu Histology Upregulated in clear cell (7), endometrioid (9), serous (20) vs mucinous (9) .011
Schwartz Histology Upregulated in clear cell (8), endometrioid (33), mixed histology (9), serous (53) vs mucinous (10) .024
TGFBR1 Gilks Stage Upregulated in grade IV (6) vs I (1) .012
upregulated in endometriod
ovarian carcinoma (9) vs clear cell
Lu Histology Ovarian carcinoma (8), mucinous .036
ovarian carcinoma (9), serous
ovarian carcinoma (19)
AXL Lancaster Histology Upregulated in normal ovary (3) vs ovarian adenocarcinoma (31) 3.2E-13
Hendrix Histology Upregulated in normal ovary (3) vs ovarian endometrioid adenocarcinoma (37) 1.3E-5
EPHA2 Lancaster Histology Upregulated in normal ovary (3) vs ovarian adenocarcinoma (31) 5.8E-6
Hendrix Histology Upregulated in ovarian endometrioid adenocarcinoma vs (37) vs normal ovary (4) 1.4E-4
Gilks Stage Upregulated in grade I (6) vs IV (4) 9.8E-4
PDGFRA Hendrix Histology Upregulated in normal ovary (4) vs ovarian serous adenocarcinoma (41) 4.2E-18
Hendrix Histology Upregulated in normal ovary (4) vs ovarian endometrioid adenocarcinoma (37) 1.9E-16
Welsh Histology Downregulated in ovarian adenocarcinoma (28) vs normal ovary (8) 7E-11
Lu Histology Downregulated in serous ovarian carcinoma (19) vs normal ovarian surface epithelium (5) 4.1E-4
